Hypertension in Pregnancy

  • Speaker Profile: The lecture is presented by Helen Jones, a professor in the Department of Physiology and Aging at the University of Florida. She is an expert in the study of how aging and physiology interact, especially in the context of pregnancy.

  • Global Context: Hypertensive disorders of pregnancy are leading causes of complications for both the mother and the infant worldwide. Early detection and proper care can significantly improve outcomes which is critical because these complications can lead to serious health risks.

  • Learning Objectives:

    • Understand the changes in the maternal cardiovascular and hematological systems during normal pregnancy. This means learning how the heart and blood vessels adapt to support both the mother’s and the baby’s needs.

    • Identify the signs and symptoms of various hypertensive disorders of pregnancy, which can help in recognizing when a mother and her child might be in danger.

    • Understand the definition of preeclampsia, a serious condition that can arise during pregnancy that needs careful management, along with the multifactorial factors contributing to its onset. For example, research studies often focus on genetic, environmental, and physiological influences on this condition, which contributes to the growing body of literature on managing preeclampsia effectively.

Cardiovascular Adaptations in Normal Pregnancy

  • Cardiac Output (CO):

    • Normal pregnancy involves a significant increase in cardiac output because the mother’s body needs to pump more blood to support the growing fetus.

    • Mechanism: This is achieved via a 10% increase in stroke volume (the amount of blood pumped with each heartbeat) and a 10% to 15% increase in pulse rate. These changes help ensure that enough oxygen and nutrients are delivered to the developing baby.

    • Timing: Changes begin as early as 5 weeks of gestation. Early pregnancy is characterized by many physiological changes as the body begins to make adjustments.

    • Peak: Cardiac output peaks during the second trimester, specifically between weeks 20 and 25. Research studies often monitor these changes closely using echocardiograms or other imaging techniques.

    • Stability: After peaking, CO remains relatively constant until delivery. While the body adapts, it is essential for healthcare providers to monitor these changes.

    • Postpartum: CO does not return to pre-pregnancy levels until the postpartum period, indicating the body’s need to adjust post-delivery as well.

  • Peripheral Vascular Resistance (PVR):

    • There is a significant reduction in peripheral vascular resistance during pregnancy. This means that the blood vessels become more relaxed, allowing blood to flow more freely.

    • Mechanism: Increased levels of estrogen and prostaglandins cause systemic vasodilation (widening of blood vessels), which is part of the body’s preparation for childbirth.

  • Blood Pressure (BP):

    • Reduced peripheral resistance leads to a small reduction in systolic blood pressure (the pressure when the heart beats) but more marked reduction in diastolic blood pressure (the pressure when the heart rests). Understanding blood pressure changes is crucial for anticipating complications during pregnancy.

Uteroplacental Vascular Remodeling

  • Non-Pregnant State: The functional endometrium (the inner lining of the uterus) contains multiple arteries originating from the uterine artery, including spiral arteries named for their coiled shape.

  • Pregnant State (Remodeling):

    • The placenta forms in early pregnancy, and its vessels undergo remodeling through the second trimester, adapting to the increased demands of pregnancy.

    • Maternal spiral arteries are remodeled to increase their radius during the first trimester. This is crucial because it ensures that the placenta receives enough blood supply.

  • Hormonal Influence on Vasculature:

    • Progesterone: Induces vascular relaxation specifically in the vessels of the uteroplacental circulation, aiding in the efficiency of nutrient and gas exchange; it does not appear to have a systemic effect.

    • Estrogen: Exerts both localized (in reproductive tissues) and systemic effects, enhances blood flow.

    • Alters the ratio of type I and type III collagen in vascular walls, which is important for maintaining the structural integrity of blood vessels.

    • Increases angiotensinogen synthesis in the liver, raising serum levels of angiotensin in maternal circulation, which plays a role in blood pressure regulation.

Renin-Angiotensin System (RAS) and Vasodilators

  • The RAS Cascade:

    • Regulated by estrogen during pregnancy. This system normally regulates blood pressure, electrolyte balance, and fluid balance, which are critical for the health of both the mother and the fetus.

    • Angiotensin II typically leads to increased salt and water retention, vasoconstriction (narrowing of blood vessels), and increased thirst/fluid intake, but its effects change during pregnancy.

  • Pregnancy-Specific RAS Modulation:

    • Despite increased angiotensinogen and angiotensin II, blood pressure decreases in normal pregnancy. This surprising outcome is due to adaptations in the mother’s body that are designed to protect fetal development.

    • The vasoconstrictive effects of angiotensin II are “blunted.” This means the body has mechanisms to counteract the potentially harmful effects of high levels of hormones like angiotensin II.

    • There is an increased vasodilator response that maintains low blood pressure, preventing complications.

  • Key Vasodilators:

    • Prostaglandins (Prostanoids): Derived from arachidonic acid; produced by the uterus and placenta.

    • Prostacyclin (PGI2PGI_2) increases fivefold during pregnancy, significantly contributing to vasodilation and inhibition of platelet aggregation, which reduces the likelihood of blood clots in the arteries.

    • The balance of prostacyclines versus thromboxane favors vasodilation and platelet inhibition, thus maintaining healthy circulation for the fetus.

    • There is no associated increase in thromboxane in normal pregnancy, which would normally promote clotting.

    • Nitric Oxide (NO): Produced by vascular endothelial cells in response to shear stress from blood flow. NO acts locally with a half-life of approximately 6 seconds and is vital for keeping blood vessels relaxed.

    • Production increases with advancing gestation, leading to more arterial wall relaxation. This is essential during pregnancy as it helps with blood flow to the placenta and the developing fetus.

Hematological Changes and Volume Expansion

  • Volume Expansion:

    • Total blood volume increases by approximately 2 L during pregnancy to support the growing uterus and fetus. This substantial increase is necessary for healthy fetal development.

    • Plasma volume increases significantly, reaching about 1250 mL by 30 weeks and remaining stable thereafter, which is a critical adaptation.

    • Mechanism: Renin and aldosterone increase up to 7 to 8 times during pregnancy, leading to salt and water retention which creates this additional blood volume.

    • Vascular compliance allows for this expansion without an abnormal increase in blood pressure, showcasing the body’s remarkable ability to adapt.

  • Hematocrit and Hemoglobin:

    • Hematocrit declines because plasma volume increases at a faster rate than red cell mass. This is important to note since it can sometimes indicate anemia if interpreted incorrectly.

    • There is a general reduction in hemoglobin content, which could lead to the need for supplementation in some cases.

  • Iron Requirements:

    • Pregnant individuals are at extreme risk of anemia due to the iron demands of the growing fetus, the placenta, and increased maternal red cell mass. This is why many healthcare providers recommend iron supplements during pregnancy.

    • Iron supplementation increases erythrocyte volume and helps minimize the decline in hematocrit, ensuring that both mother and baby stay healthy.

  • Timing of Changes:

    • Plasma volume increases by 10% at weeks 8 to 10 of gestation (similar to changes seen in the menstrual cycle), indicating how early these changes begin. It highlights the need for monitoring in early pregnancy.

    • By 10 weeks, cardiac output and volume adaptations are no longer solely dependent on plasma expansion, showing the interconnectedness of these physiological systems.

Rationales for Physiological Adaptations

  • Nutrient Delivery: Significant increases in uterine blood flow are required, rising from 45 mL/min in the non-pregnant state to 750 mL/min in the pregnant state. This dramatic increase is critical for fetal health.

  • Fetal Growth: The blood flow increase is vital for transferring enough oxygen and nutrients for healthy fetal growth over the 40-week gestation period, shedding light on why healthcare monitoring during this time is essential.

  • Protection During Delivery: The increased blood volume acts as a safeguard against risks associated with birth, such as hemorrhage, which can be life-threatening.

Classification of Hypertensive Disorders of Pregnancy (HDP)

  • Hypertension Types:

    • Chronic Hypertension: High blood pressure that predates pregnancy or is diagnosed before 20 weeks. It may persist postpartum and increases the risk of preeclampsia.

    • Gestational Hypertension: New onset of high blood pressure after 20 weeks without maternal organ damage or proteinuria. It usually resolves postpartum but flags a risk for future hypertension. Screening for hypertension is crucial during prenatal visits to catch these signs early.

  • Progressive Severity conditions:

    • Preeclampsia: Diagnosed after 20 weeks. Characterized by high blood pressure, proteinuria, and signs of organ damage (liver or kidneys). For a deeper understanding of preeclampsia, recent literature focuses on its genetic and environmental risk factors.

    • Eclampsia: Defined by the onset of seizures in an individual with preeclampsia. It is a medical emergency that requires immediate delivery of the baby and placenta, underlining the importance of monitoring.

    • HELLP Syndrome: A severe form of preeclampsia. The acronym stands for Hemolysis, Elevated Liver enzymes, and Low Platelet count and has been the focus of recent research for its long-term consequences on women’s health.

Preeclampsia: Diagnosis and Symptoms

  • Clinical Presentation:

    • Severe headache and blurred vision, which might suggest a rapid increase in blood pressure and should never be ignored.

    • Upper abdominal pain (in severe cases), which is often accompanied by other symptoms indicating fetal distress.

    • Swelling (edema) of results in the hands, feet, or face, a common symptom that can sometimes be confused with normal pregnancy symptoms.

    • Rapid weight gain commonly linked to fluid retention which may signal the need for further evaluation.

    • Shortness of breath that can arise from fluid build-up or other complications; it indicates the need for medical evaluation.

    • Decreased fetal movements, which can indicate fetal distress or complications requiring immediate attention.

  • Diagnosis Note: Diagnosis is not based on these symptoms alone but requires clinical findings (blood pressure readings and lab work); however, these symptoms after 20 weeks are strong indicators.

  • Incidence: Affects 3% to 5% of all pregnancies, though some regions in the US report rates as high as 10% to 12%. Research studies often track these incidences to better understand the condition.

Clinical Management of Hypertension in Pregnancy

  • Thresholds:

    • Regular monitoring: Blood pressure at or above 140/90 indicates caution.

    • Urgent treatment/Hospitalization: Severe hypertension measured at 160/110, which requires immediate attention. These thresholds are part of standardized protocols that healthcare providers follow.

  • Permitted Medications:

    • Labetalol: Often used as the first choice in managing hypertension during pregnancy.

    • Nifedipine: Another medication commonly prescribed to manage high blood pressure in pregnant individuals.

    • Methyldopa: Used but with careful monitoring as it may have side effects.

  • Contraindicated Medications:

    • ACE inhibitors and ARBs (Angiotensin II Receptor Blockers) are avoided due to developmental risks to the fetus, which is an important aspect of managing maternal health.

Pathophysiology and Etiology of Preeclampsia

  • Placental Origin: Triggered by abnormal placental development or factors released from the placenta that can lead to systemic issues in the mother’s body.

  • Defective Remodeling:

    • Trophoblast cells fail to appropriately invade and remodel the spiral arteries, leading to poor placental blood flow.

    • In preeclampsia, trophoblasts may only line the upper third of the artery rather than the whole vessel, causing high resistance to blood flow.

  • Shear Stress Mechanism:

    • Because the vessels are not remodeled (small bore) but blood volume has increased, blood velocity is significantly higher.

    • High-velocity blood causes shear stress and damage to the fragile syncytial layer of the placental villous tree, highlighting the risks of inadequate blood supply.

    • Damage leads to apoptosis and the release of pro-inflammatory placental debris into maternal circulation, showcasing the interconnectedness of the placental health and maternal wellness.

  • Systemic Response:

    • Pro-inflammatory material leads to maternal endothelial cell dysfunction, adversely affecting maternal health.

    • Exaggerated inflammatory response prevents normal vascular adaptation, increasing the risk of severe complications.

  • RAS and Vasodilator Abnormalities:

    • RAS: Preeclamptic pregnancies have lower circulating RAS components but show increased sensitivity to Angiotensin II, leading to heightened risk factors during pregnancy.

    • Vasodilators: Reduced prostacyclin production starts around week 13 to 16 due to hormonal changes linked to preeclampsia.

    • Thromboxane levels rise from week 21, favoring platelet activation and vasoconstriction, which pose serious risks for the mother.

    • Nitric Oxide: Associated with increased endogenous inhibitors of nitric oxide synthase, leading to less NO, which is crucial for vessel dilation. Research often focuses on these pathways to understand preeclampsia better.

Risk Factors and Long-term Impacts

  • Known Risk Factors:

    • First pregnancies (primiparity) are particularly susceptible due to the body's first-time adaptations.

    • History of preeclampsia in previous pregnancies raises future risks and is a critical component of maternal history evaluations.

    • Pre-existing conditions: Hypertension, elevated BMI, or Type 1/Type 2 diabetes can worsen pregnancy outcomes.

    • Genetics: Up to 55% of risk is thought to be inherited, which has been the focus of many genetic studies looking into preeclampsia.

  • Short-term Risks: Seizures, stroke, coma, and placental abruption (detachment causing hemorrhage) highlight the emergencies that can arise.

  • Long-term Impacts:

    • Postpartum Preeclampsia: Onset can occur up to 6 weeks after delivery even if blood pressure was normal during pregnancy, which underscores the importance of continued monitoring post-delivery.

    • Cardiovascular Disease: History of preeclampsia or hypertensive disorders increases the risk of future cardiovascular disease, thus warranting long-term follow up.

    • Mental Health: Increased risk of postpartum depression and anxiety due to the stress of complications experienced during pregnancy, which is important considering the psychological impacts of severe pregnancy-related illnesses.

Prediction and Prevention

  • Prediction Tools:

    • Maternal history and pre-pregnancy blood pressure form the basis for predicting potential complications.

    • First-trimester biomarkers aim to enhance prediction, such as the ratio of Placental Growth Factor (PlGF) to sFLT in the blood, which researchers are studying more in-depth.

  • Prevention via Low-Dose Aspirin:

    • Administered after 12 weeks of gestation for high-risk individuals as a preventative measure, which is based on growing evidence in clinical studies.

    • Mechanism of Action:

    • Reduces platelet aggregation by inhibiting thromboxane production, which enhances prostacyclin production (promoting vasodilation).

    • Improves blood flow to the placenta and prevents clot formation in spiral arteries, showing the value of interventions based on existing literature.

    • Ongoing Research: Studies are investigating if aspirin has direct impacts on trophoblast function or the placenta itself, with outcomes potentially changing clinical practices for managing high-risk pregnancies.